Tyra Biosciences (TYRA) Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025 summary

Key clinical data and drug differentiation

• TYRA-300 demonstrated superior efficacy and selectivity in late-line metastatic urothelial cancer, with a confirmed ORR of 54.5% at 90 mg, outperforming standard therapies and showing a favorable safety profile with reduced FGFR2/1/4-related toxicities.

• Lower doses (50/60 mg) in NMIBC and pediatric settings showed minimal ALT/AST increases, supporting a statin-like safety profile and reinforcing differentiation from competitors.

• Competitor data (Loxo/Lilly) required much higher drug exposure for similar efficacy, with higher rates of adverse events like diarrhea, highlighting TYRA-300's advantage.

Market opportunity and competitive landscape

• FGFR-driven metastatic urothelial cancer market is limited by toxicity and tolerability issues of current drugs, with high rates of dose reductions and discontinuations due to FGFR2-driven side effects.

• Oral therapies are preferred by both patients and urologists, especially in NMIBC, due to convenience and economic incentives for in-office dispensing.

• NMIBC represents a larger opportunity, with oral FGFR3 inhibitors positioned to disrupt the market dominated by intravesical and surgical options.

Clinical development and upcoming milestones

• Ongoing dose expansion in metastatic urothelial cancer at 90/100 mg and NMIBC at 50/60 mg, with randomized cohorts and open-label studies.

• Initial three-month CR data in NMIBC and six-month efficacy data in achondroplasia expected early next year, with safety data anticipated this year.